Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Pseudoxanthoma elasticum

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    8 result(s) found for: Pseudoxanthoma elasticum. Displaying page 1 of 1.
    EudraCT Number: 2014-005263-33 Sponsor Protocol Number: AUG-201202-EyNeP Start Date*: 2015-04-29
    Sponsor Name:Medizinische Fakultät der Universität Bonn
    Full Title: Intravitreal Aflibercept (Eylea®) for therapy of choroidal neovascularization and fibrovascular proliferation in patients with Pseudoxanthoma elasticum
    Medical condition: Choroidal neovascularizations and fibrovascular proliferations in patients with Pseudoxanthoma elasticum
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10037150 Pseudoxanthoma elasticum PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-004021-16 Sponsor Protocol Number: FIM-PXE-2016-01 Start Date*: 2018-10-31
    Sponsor Name:Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (FIMABIS)
    Full Title: Response to oral lansoprazole in inorganic pyrophosphate levels in patients with Grönblad-Stranberg disease (Pseudoxanthoma Elasticum)
    Medical condition: Grönblad-Stranberg disease (Pseudoxanthoma Elasticum)
    Disease: Version SOC Term Classification Code Term Level
    19.1 10010331 - Congenital, familial and genetic disorders 10037150 Pseudoxanthoma elasticum PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-006231-49 Sponsor Protocol Number: CRFB002ADE03 Start Date*: 2007-07-24
    Sponsor Name:Department of Ophthalmology, Bonn University
    Full Title: Ranibizumab in choroidal neovascularization (CNV) due to Pseudoxanthoma elasticum (PXE, Groenblad-Strandberg Syndrome)
    Medical condition: Pseudoxanthoma elasticum (PXE) is an inherited systemic disease characterized by changes in the elastic tissue. Pseudoxanthoma elasticum mainly affects the skin, eyes, heart, and GI system. The cut...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10037150 Pseudoxanthoma elasticum LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2022-000676-19 Sponsor Protocol Number: DS1211-A-U201 Start Date*: 2022-07-18
    Sponsor Name:Clinical Director, Daiichi Sankyo, Inc.
    Full Title: A Phase 2, 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of DS-1211b in Individuals with Pseudoxanthoma Elasticum
    Medical condition: Pseudoxanthoma Elasticum (PXE)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10037150 Pseudoxanthoma elasticum PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2020-004000-33 Sponsor Protocol Number: INZ701-201 Start Date*: 2021-06-10
    Sponsor Name:Inozyme Pharma, Inc.
    Full Title: A Phase 1/2, Open-Label, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INZ-701 Followed by an Open-Label Long-Term Extension Period i...
    Medical condition: Treatment of patients with ABCC6 Deficiency Manifesting as Pseudoxanthoma elasticum (PXE)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10037150 Pseudoxanthoma elasticum PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-002109-24 Sponsor Protocol Number: 09122019 Start Date*: 2019-08-01
    Sponsor Name:Tampere University Hospital
    Full Title: Oral Disodiumpyrophosphate (Na2H2PPi) Absorption in Pseudoxanthoma Elasticum
    Medical condition: Pseudoxanthoma elasticum
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000434-34 Sponsor Protocol Number: UMCU-VASC-CO-003 Start Date*: 2023-04-12
    Sponsor Name:University Medical Centre Utrecht
    Full Title: A placebo-controlled, double-blind randomized trial evaluating the effect of etidronate in young patients with pseudoxanthoma elasticum on ectopic mineralization.
    Medical condition: Pseudoxanthoma elasticum
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-001421-55 Sponsor Protocol Number: CRFB002GFR02 Start Date*: 2013-06-13
    Sponsor Name:Novartis Pharma S.A.S
    Full Title: An open-label Extended Clinical Protocol of ranibizumab to evaluate Safety and Efficacy in rare VEGF driven ocular diseases.
    Medical condition: Choroidal neovascularization not related to wet Age-related macular degeneration (wAMD), pathologic myopia (PM)or Pseudoxanthoma elasticum (PXE), as well as in Macular Edema (ME) not related to Ret...
    Disease: Version SOC Term Classification Code Term Level
    18.0 10015919 - Eye disorders 10047060 Retina, choroid and vitreous haemorrhages and vascular disorders HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 23:41:09 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA